[1]
|
Kidney disease:improving global outcomes (KDIGO) CKD-MBD work group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)[J]. Kidney Int Suppl, 2009, 76:S1-S130. http://med.wanfangdata.com.cn/Paper/Detail/PeriodicalPaper_PM19644521 |
[2]
|
Kidney disease:improving global outcomes (KDIGO) CKD-MBD update work group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)[J]. Kidney Int Suppl, 2017, 7:1-59. doi: 10.1016/j.kisu.2017.04.001 |
[3]
|
Alem AM, Sherrard DJ, Gillen DL, et al. Increased risk of hip fracture among patients with end-stage renal disease[J]. Kidney Int, 2000, 58:396-399. doi: 10.1046/j.1523-1755.2000.00178.x |
[4]
|
Nickolas TL, McMahon DJ, Shane E. Relationship between moderate to severe kidney disease and hip fracture in the United States[J]. J Am Soc Nephrol, 2006, 17:3223-3232. doi: 10.1681/ASN.2005111194 |
[5]
|
Mittalhenkle A, Gillen DL, Stehman-Breen CO. Increased risk of mortality associated with hip fracture in the dialysis population[J]. Am J Kidney Dis, 2004, 44:672-679. doi: 10.1016/S0272-6386(04)00958-8 |
[6]
|
Tentori F, McCullough K, Kilpatrick RD, et al. High rates of death and hospitalization follow bone fracture among hemodialysis patients[J]. Kidney Int, 2014, 85:166-173. doi: 10.1038/ki.2013.279 |
[7]
|
Iimori S, Mori Y, Akita W, et al. Diagnostic usefulness of bonemineral density and biochemical markers of bone turnover inpredicting fracture in CKD stage 5D patients-a single-centercohort study[J]. Nephrol Dial Transplant, 2012, 27:345-351. doi: 10.1093/ndt/gfr317 |
[8]
|
West SL, Lok CE, Langsetmo L, et al. Bone mineral density predictsfractures in chronic kidney disease[J]. J Bone Miner Res, 2015, 30:913-919. doi: 10.1002/jbmr.2406 |
[9]
|
Haghverdi F, Mortaji S, Soltani P, et al. Effect of raloxifene onparathyroid hormone in osteopenic and osteoporoticpostmenopausal women with chronic kidney disease stage 5[J]. Iran J Kidney Dis, 2014, 8:461-466. http://europepmc.org/abstract/med/25362221 |
[10]
|
Jamal SA, Ljunggren O, Stehman-Breen C, et al. Effects ofdenosumab on fracture and bone mineral density by level of kidneyfunction[J]. J Bone Miner Res, 2011, 26:1829-1835. doi: 10.1002/jbmr.403 |
[11]
|
EVOLVE Trial Investigators, Chertow GM, Block GA, et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis[J]. N Engl J Med, 2012, 367:2482-2494. doi: 10.1056/NEJMoa1205624 |
[12]
|
Block GA, Kilpatrick RD, Lowe KA, et al. CKD-mineral and bone disorder and risk of death and cardiovascular hospitalization inpatients on hemodialysis[J]. Clin J Am Soc Nephrol, 2013, 8:2132-2140. doi: 10.2215/CJN.04260413 |
[13]
|
Chartsrisak K, Vipattawat K, Assanatham M, et al. Mineral metabolism and outcomes in chronic kidney disease stage 2-4 patients[J]. BMC Nephrol, 2013, 14:14-20. doi: 10.1186/1471-2369-14-14 |
[14]
|
Eddington H, Hoefield R, Sinha S, et al. Serum phosphate and mortality inpatients with chronic kidney disease[J]. Clin J Am Soc Nephrol, 2010, 5:2251-2257. doi: 10.2215/CJN.00810110 |
[15]
|
Fouque D, Roth H, Pelletier S, et al. Control of mineral metabolism and bone disease in haemodialysis patients:which optimal targets?[J]. Nephrol Dial Transplant, 2013, 28:360-367. doi: 10.1093/ndt/gfs404 |
[16]
|
Gross P, Six I, Kamel S, et al. Vascular toxicity of phosphate in chronic kidney disease:beyond vascular calcification[J]. Circ J, 2014, 78:2339-2346. doi: 10.1253/circj.CJ-14-0735 |
[17]
|
Hill KM, Martin BR, Wastney ME, et al. Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease[J]. Kidney Int, 2013, 83:959-966. doi: 10.1038/ki.2012.403 |
[18]
|
Block GA, Wheeler DC, Persky MS, et al. Effects of phosphate binders in moderate CKD[J]. J Am Soc Nephrol, 2012, 23:1407-1415. doi: 10.1681/ASN.2012030223 |
[19]
|
Di Iorio B, Bellasi A, Russo D, et al. Mortality in kidney disease patients treated with phosphate binders:a randomized study[J]. Clin J Am Soc Nephrol, 2012, 7:487-493. doi: 10.2215/CJN.03820411 |
[20]
|
Di Iorio B, Molony D, Bell C, et al. Sevelamer versus calcium carbonate in incident hemodialysis patients:results of an openlabel 24-month randomized clinical trial[J]. Am J Kidney Dis, 2013, 62:771-778. doi: 10.1053/j.ajkd.2013.03.023 |
[21]
|
Jamal SA, Vandermeer B, Raggi P, et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality inpatients with chronic kidney disease:an updated systematic reviewand meta-analysis[J]. Lancet, 2013, 382:1268-1277. doi: 10.1016/S0140-6736(13)60897-1 |
[22]
|
Karavetian M, de Vries N, Elzein H, et al. Effect of behavioral stage-based nutrition education on management of osteodystrophy among hemodialysis patients, Lebanon[J]. Patient Educ Couns, 2015, 98:1116-1122. doi: 10.1016/j.pec.2015.05.005 |
[23]
|
Floege J, Kim J, Ireland E, et al. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population[J]. Nephrol Dial Transplant, 2011, 26:1948-1955. doi: 10.1093/ndt/gfq219 |
[24]
|
Spiegel DM, Brady K. Calcium balance in normal individuals and in patients with chronic kidney disease on low- and high-calcium diets[J]. Kidney Int, 2012, 81:1116-1122. doi: 10.1038/ki.2011.490 |
[25]
|
St Peter WL, Li Q, Liu J, et al. Cinacalcet use patterns and effect on laboratory values and other medications in a large dialysis organization, 2004 through 2006[J]. Clin J Am Soc Nephrol, 2009, 4:354-360. doi: 10.2215/CJN.05241008 |
[26]
|
Denburg MR, Tsampalieros AK, de Boer IH, et al. Mineral metabolism and cortical volumetric bone mineral density inchildhood chronic kidney disease[J]. J Clin Endocrinol Metab, 2013, 98:1930-1938. doi: 10.1210/jc.2012-4188 |
[27]
|
Ok E, Asci G, Bayraktaroglu S, et al. Reduction of dialysate calcium level reduces progression of coronary artery calcification and improves low bone turnover in patients on hemodialysis[J]. J Am Soc Nephrol, 2016, 27:2475-2486. doi: 10.1681/ASN.2015030268 |
[28]
|
Spasovski G, Gelev S, Masin-Spasovska J, et al. Improve-ment of bone and mineral parameters related to adynamic bone disease by diminishing dialysate calcium[J]. Bone, 2007, 41:698-703. doi: 10.1016/j.bone.2007.06.014 |
[29]
|
Thadhani R, Appelbaum E, Pritchett Y, et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease:the PRIMO randomized controlled trial[J]. JAMA, 2012, 307:674-684. doi: 10.1001/jama.2012.120 |
[30]
|
Li XH, Feng L, Yang ZH, et al. The effect of active vitamin d on cardiovascular outcomes in predialysis chronic kidney diseases:a systematic review and meta-analysis[J]. Nephrology (Carlton), 2015, 20:706-714. doi: 10.1111/nep.12505 |
[31]
|
Parfey PS, Drüeke TB, Block GA, et al. The effects of cinacalcet in older and younger patients on hemodialysis:the Evaluation of Cinacalcet HCI Therapy to Lower Cardiovascular Events (EVOLVE) trial[J]. Clin J Am Soc Nephrol, 2015, 10:791-799. doi: 10.2215/CJN.07730814 |
[32]
|
Parfrey PS, Chertow GM, Block GA, et al. The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet:the EVOLVE trial[J]. J Clin Endocrinol Metab, 2013, 98:4834-4844. doi: 10.1210/jc.2013-2975 |
[33]
|
Behets GJ, Spasovski G, Sterling LR, et al. Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism[J]. Kidney Int, 2015, 87:846-856. doi: 10.1038/ki.2014.349 |
[34]
|
Raggi P, Chertow GM, Torres PU, et al. The advance study:a randomized study to evaluate the effects of cinacalcet plus low-dosevitamin D on vascular calcification in patients on hemodialysis[J].Nephrol Dial Transplant, 2011, 26:1327-1339. doi: 10.1093/ndt/gfq725 |